Cyproheptadine: A Potentially Effective Treatment for Functional Gastrointestinal Disorders in Children

Pediatr Ann. 2017 Mar 1;46(3):e120-e125. doi: 10.3928/19382359-20170213-01.


Functional gastrointestinal disorders (FGIDs) negatively affect children's quality of life and health care costs. It has been proposed that alteration of gut serotonin leads to gastrointestinal dysmotility, visceral hypersensitivity, altered gastrointestinal secretions, and brain-gut dysfunction. Cyproheptadine, a serotonin antagonist, has been shown to be a potentially effective and safe treatment option in children who meet the clinical criteria for FGIDs. Well-designed multicenter trials with long-term follow-up are needed to further investigate its efficacy. [Pediatr Ann. 2017;46(3):e120-e125.].

Publication types

  • Review

MeSH terms

  • Child
  • Cyproheptadine / therapeutic use*
  • Gastrointestinal Agents / therapeutic use*
  • Gastrointestinal Diseases / drug therapy*
  • Gastrointestinal Diseases / physiopathology
  • Humans
  • Treatment Outcome


  • Gastrointestinal Agents
  • Cyproheptadine